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Abstract
Cardiology has recently witnessed the production of an overwhelming amount of data
through the advances made in genetics and molecular biology research. Understanding of
genetics has tremendous potential to aid in the prevention, diagnosis and treatment of the
majority of diseases. Despite the high level of publicity for research discoveries, clinicians
have had difficulty in discriminating between what is still basic research and what can be
applied to patients. The fact is that we still lack the technology to perform genetic testing in a
time frame that is acceptable to clinicians. Meanwhile, then, the only option is to rely on
clinical tests that can help us better stratify the individuals at risk for a disease. For example,
Brugada syndrome has benefited tremendously from genetics and molecular biology since
its initial description in 1992. Genetics will provide a more definitive diagnosis for the
disease in the future. For the time being, though, research has shown that the administration
of an intravenous class I antiarrhythmic is very useful in identifying patients with a concealed
form of the disease.
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Introduction
Over the past 50 years, the survival and quality of life of
patients with cardiac disease has improved tremendously.
Despite continued progress in technology and drug
therapy, it seems that progress may have reached a plateau.
The majority of our patients suffer from structural heart dis-
eases, such as atherosclerosis and primary myocardial
disease, that often progress despite our best efforts.
The situation is completely different, however, when
cardiac arrest strikes a healthy young person with no pre-
vious medical history. In this case, there is pressure not
only on the patient and physician but also on family
members, as there is a higher likelihood that the patient is
suffering from a genetically determined disease predis-
posing to sudden death. It is at this point that there is a
clash between the bench and the bedside, with physi-
cians and family demanding a genetic test that will
provide a definite diagnosis. The advances in molecular
cardiology and genetics have been spectacular if one
thinks that it has been only 10 years since the identifica-
tion of the first gene predisposing to a familial cardiac
disease. It is expected that our knowledge of cardiac
disease will grow exponentially in the next few years
thanks to the advances in the Human Genome Project.
The reality, though, is that the technology has not yet
evolved enough to be able to complete a genetic screen
in a few days.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Brugada
Among the different diseases which are genetically deter-
mined, Brugada syndrome has benefited tremendously
from the developments in molecular biology. The diagnosis
is based on a clinical-electrocardiographic criteria consist-
ing of syncopal or aborted sudden death episodes occur-
ring in patients with a structurally normal heart, who also
present with a characteristic ECG pattern of right bundle
branch block and ST segment elevation in leads V1 to V3.
The episodes of syncope and sudden death (aborted) are
caused by fast polymorphic ventricular tachycardias[1].
Etiology and epidemiology
The first case series showing the link of the ECG pattern
with sudden death was published in 1992 [2]. Since
then it has been identified in all parts of the world, being
the most important cause of sudden death in young
males in Southeast Asia [3], and also claiming some of
the deaths from sudden infant death syndrome [4]. It is a
highly fatal disease, with recurrence of events of 30% at
3 years. There is no medical therapy to prevent recur-
rence. The implantable defibrillator is the only therapy
that has been shown to possibly improve survival of
these individuals [1].
This syndrome is genetically determined and in some
cases is caused by mutations in the gene SCN5A, on
chromosome 3[5]. This gene encodes the human cardiac
sodium channel. The pattern of transmission described
so far in this disease is autosomal dominant. As is the
case with the other familial cardiac diseases, some of the
families studied do not present any mutation in the
SCN5A gene, indicating that the disease is heteroge-
neous, caused by mutations in more than one gene.
Functional analysis of the mutations in Xenopus oocytes
shows that the mutant channel has loss of function, creat-
ing heterogeneity of refractory periods, a perfect
substrate for reentrant arrhythmias. Further electro-
physiologic studies have shown that the effect of the
mutation is temperature-dependent, worsening channel
function at temperatures approaching the physiological
range [6].
It is difficult to estimate the real prevalence of the disease
due to the fact that the ECGS of affected patients are vari-
able, normalizing during certain periods of time. Therefore,
like other genetically determined diseases, such as the
long QT syndrome or familial hypertrophic cardiomyopa-
thy, the lack of clinical data pointing to the presence of
disease does not exclude a family member from being
affected. This complicates the identification of individuals
at risk, and increases the pressure on physicians and rela-
tives of a patient who has Brugada syndrome.
The ECG pattern can be modulated by autonomic and
pharmacological interventions [7]. Administration of a
sodium channel blocker may unmask the ECG pattern in
those individuals who present with a normal ECG;
however, this test has not been validated for identifying
individuals at risk, mainly because of the lack of a gold
standard. The description of one of the genes causing
Brugada syndrome has enabled family members of the
individuals carriers of the disease to be screened; conse-
quently, the sensitivity and specificity of the antiarrhythmic
test has been analyzed in this specific population [8]. The
results of our investigation were encouraging, as the test
identified all the individuals who carried the abnormal gene
and all the affected individuals who had transient normal-
ization of the ECG. None of the controls showed the char-
acteristic ECG pattern after the administration of the class
IC antiarrhythmic drug. The study also demonstrated that
the risk of sudden death in individuals with the intermittent
ECG pattern is the same as the risk for individuals with
persistent ST segment elevation.
Genetic screening for sudden death
Genetic testing can provide firm evidence for or against
the diagnosis of familial diseases. Indeed, it has the poten-
tial to be 100% sensitive and specific in identifying individ-
uals at risk. There is at present an important limitation,
however: as unbelievable as it may seem, this is actually
the lack of technology to perform a fast genetic screen.
Physicians meanwhile have to rely on clinical parameters to
risk stratify those individuals affected by a lethal disease.
These parameters are neither sensitive nor specific
enough. Despite the fact that family history of sudden
death is helpful, it provides prognostic information only if
the death was clearly related to the same disease [9]. For
example, in hypertrophic cardiomyopathy, patients with
mutations in troponin T can have subclinical hypertrophy
[10], in long QT syndrome 5–15% of the patients are diag-
nosed incorrectly if the diagnosis is based only on the elec-
trocardiographic criteria [11], and in Brugada syndrome,
there can be transient normalization of the ECG, which
complicates the identification of affected individuals.
Among the multiple clinical tests performed in individuals
who present with syncope or aborted sudden death of
unknown etiology and a normal ECG, the administration of
intravenous ajmaline, procainamide or flecainide (doses
shown in Table 1) has proven very useful for unmasking
Brugada syndrome. The test is safe, but the triggering of
ventricular arrhythmias during the test has been
described, with an incidence of sustained ventricular
arrhythmia of 0.5% (P Brugada, unpublished data). It is
mandatory then that the test be performed in a safe envi-
ronment, with cardiopulmonary resuscitation equipment
available. The test has been shown to be reliable in identi-
fying both the carriers of SCN5A mutations and the indi-
viduals who present with transient normalization of the
ECG. Further research is required to validate this test in
individuals with mutations in other genes.c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
http://cvm.controlled-trials.com/content/1/1/045
Conclusion
Brugada syndrome is being recognized worldwide as a
cause of sudden death in the young population with struc-
turally normal hearts. Research in recent years has shown
that the risk of sudden death is 30% at 3 years, both for
symptomatic and asymptomatic individuals. While the ECG
is variable and can normalize at follow-up, the patients
remain at the same high risk of events. It is then of para-
mount importance to be able to diagnose these individuals.
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Table 1
Intravenous agents used to unmask ECG abnormalities.
Antiarrhythmic agent Dose Infusion time
Ajmaline 1 mg/kg 5 min
Flecainide 2 mg/kg 10 min
Procainamide 10 mg/kg 10 min